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Characterisation of antimitotic products from marine organisms that
disorganise the microtubule network: ecteinascidin 743,
isohomohalichondrin-B and LL-15
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Summary The effect of selected marine compounds with anti-tumoral activity on the cell microtubule network
was tested by immunofluorescence analyses, or by other in vitro analyses involving competition with colchicine
or with GTP for tubulin binding and tubulin polymerisation, studies that were carried out in parallel with other
microtubule poisons used as controls. Three compounds were found to disorganise the microtubule network:
isohomohalichondrin B, LL-15 and ecsteinascidin 743. The first two compounds prevent microtubule assembly
and GTP binding to tubulin. Ecteinascidin 743 disorganises the microtubule network but it does not seem to
interact directly with tubulin.
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Microtubules are tubulin polymers involved in different
functions, including the determination of cell morphology,
the regulation of intracellular organisation or to facilitate
chromosome segregation, which takes place during the
process of cell division. Thus, compounds that interfere
with the mechanism of microtubule polymerisation could
inhibit assembly of the mitotic spindle and consequently
could prevent cell division. This characteristic has been taken
into account when identifying those compounds as anti-
tumoral agents. Different natural and synthetic compounds
have been used as anti-tumoral drugs based on their ability to
affect the microtubule polymerisation-depolymerisation pro-
cess (Rowinsky and Donehower, 1991; Hamel, 1990; Diez et
al., 1987; Luduefia et al., 1989; Bai et al., 1991; Sullivan et
al., 1990; Huang et al., 1985; Hoeberek et al., 1976; Wheeler
et al., 1982; Schiff et al., 1979). Different mechanisms have
been postulated for the action of different microtubule
poisons. Some of those compounds prevent microtubule
polymerisation by binding to tubulin in a similar way to
colchicine, the first compound described to affect microtubule
assembly (Taylor, 1965). Other compounds interfere with the
binding of GTP to tubulin (Bai et al., 1991). Also, the
presence of certain microtubule-associated proteins, which
could be different in cells of different origin, could modulate
the action of microtubule inhibitors (Boas et al., 1994). As
different tumour cells may be resistant to some of those
microtubule poisons (Beck, 1987), a search for novel
compounds from new sources should be carried out.
Natural antimicrotubular compounds mainly originate
from plant or fungi, and they usually show their inhibitory
effect in the range of 10-6M (Hamel, 1990). Synthetic or semi
synthetic compounds have also been used. An example is
nocodazol (Hoeberek et al., 1976). In this work we tested a
family of compounds from marine animals, as those animals
have been indicated as a source for microtubule poisons (Bai
et al., 1991) that could interfere with cell proliferation (Flam,
1994). Additionally, a semisynthetic product, LL-15
(Gordaliza et al., 1996), with a structure related to
podophylotoxin, a microtubule poison (Hamel, 1990), was
tested. Our results indicate that three of the tested
compounds alter the cell microtubule network at a low
concentration range.
These compounds are isohomohalichondrin B (from the
sponge Lissodendoryx sp, with activity in lung cancer or
melanoma cell lines), (Hirata and Uemura, 1986), ecteinasci-
din 743 (from the tunicate Ecteinascidia turbinata, also with
activity in lung cancer and in breast cancer and melanoma
cell lines) and the compound LL-15. In this study we
characterised the antimitotic effect of these compounds.
Materials and methods
Chemicals and antibodies
Colcemid (demecolcine) and nocodazole were obtained from
Sigma. Ring A-4-[3H]colchicine and [8-3H]GTP (specific
activity 1 mCi mmol- and 7.7 Ci mmol- respectively)
were from Amersham. Isohomohalichondrin B, ecteinascidin
743, LL-15 and the other marine compounds (digonozate
triacetate, Palau's amine, thiocoraline, benzoascidermin, MB-
3 and mycoperoxide B) were provided by PharmaMar. The
structures of some of these compounds and those of some
isomers are shown in Figure 1. Stock solutions of these drugs
were made in dimethyl sulphoxide (DMSO) and stored at
-20°C. Anti-tubulin, anti-actin and anti-vimentin mono-
clonal antibodies and fluorescein or Texas red-labelled goat
anti-mouse immunoglobulins were from Amersham.
Cell culture
COS-1 (Gluzman, 1981), HeLa or mouse P388 cells were
grown in Dulbecco's modified Eagle medium supplemented
with 5% fetal bovine serum. Cells were plated onto 10 x 10
mm coverslips in 24-well tissue culture plates at a density of
100 cells mm-2 and cultured for 1 day. The cells were then
treated with different concentrations of the drugs for 2 -
24 h. After the treatment, in selected cases, the culture
medium containing the drug was removed and fresh medium
was added to allow cell recovery.
Inhibition ofgrowth
COS-1, HeLa or P388 (lymphoid line) cells were seeded at
4 x 103 cells per well in 1 ml aliquots of culture medium, then
incubated for 18 h. The medium was then replaced with
culture medium containing the corresponding drug. All
determinations were carried out in triplicate.
Cells were counted in a Coulter counter ZM at 6, 24, 48
and 72 h after drug addition. In the case of COS-1 and HeLa
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Figure 1 Structure of the compounds with activity on microtubule organisation. (a) IHB, (b) ET 743 (b') ET 735. (b") ET 736, (c)
LL-15 and (c') LL-16.
cultures, the cells were previously trypsinised. All counts (net
cells per well) represent the average of three wells and
indicate per cent of growth relative to cultures without drug.
Immunofluorescence analysis
The coverslips with treated cells were fixed with 4%
paraformaldehyde in phosphate-buffered saline (PBS) (w/v)
(Osborn and Weber, 1982). Preparations were washed twice
with PBS, treated with sodium borohydride ( 1 mg ml-') and
permeabilised with 0.2% Triton X-100. The coverslips were
washed with 1% bovine serum albumin (BSA) in PBS (w/v).
Afterwards, the cells were overlaid for 1 h at room
temperature with 20 ,ul of mouse monoclonal anti-a- or anti
,B-tubulin antibodies diluted 1:1000 in PBS-BSA 1% (w/v).
After washing with PBS, coverslips were overlaid with
fluorescein or Texas red-labelled goat anti-mouse antibodies
diluted 1:50 in PBS-BSA 1%. The coverslips were mounted
with Mowiol and stored in the dark at 4°C until observation.
Negative controls were routinely prepared by omitting the
first antibody. These typically gave a weak fluorescence
(requiring about ten times more exposure time) that was
distributed diffusely within the cells.
Microtubule protein preparation
Microtubules were purified from bovine brain as described
previously by Karr et al. (1982). Tubulin depleted of
microtubule-associated proteins was isolated from microtu-
bules by phosphocellulose chromatography (Weingarten et
al., 1975).
Microtubule polymerisation
Microtubule protein (2 mg ml-') was incubated in the absence
or presence of different concentrations of drugs in a buffer
containing 80 mM Pipes (pH 6.9), 1 mM magnesium chloride, 1
mM EGTA, 1 mM GTP and DMSO 10% for 30 min at 35°C.
The use of DMSO to facilitate microtubule assembly was
described previously in the pioneer work of Himes et al.
(1977). The polymerised protein was pelleted in a Beckman
airfuge for 5 min at maximum speed at room temperature, and
quantified by electrophoresis. The same assay was performed
with tubulin depleted of associated proteins.
Colchicine binding assay
The colchicine binding activity of purified brain tubulin was
measured as reported by Sherline et al. (1974). The assay
was performed as follows: 50 Mg of microtubule protein (1
mg ml-') in MES 100 mM (pH 6.4), 0.5 mM magnesium
chloride and 2 mM EGTA (buffer A), were incubated with
10-6M [3H]colchicine (1 mCi mmol-1) in the absence or
presence of drug for 90 min at 35°C in the dark.
Equilibrium was attained after 30 min at the protein
concentrations used in the assay. After incubation, 0.5 ml
of activated charcoal solution (6 mg ml-') in buffer A was
added and incubated for 10 min at 4°C. The samples were
then centrifuged in a microfuge for 10 min at 4°C. The
supernatant was collected and the radioactivity measured
after the addition of 5 ml of Scintillation Cocktail Optiphase
'Hisafe' (Wallac).
Assay for GTP binding to tubulin
An aliquot (50,ug) of tubulin depleted of microtubule-
associated protein (0.3 mg ml-') was incubated in the
absence or presence of drugs in buffer A plus 30 mM
[8-3H]GTP. The mixture was incubated at room temperature
for 5 min to allow [3H]GTP binding to tubulin. Unbound
[3H]GTP. was separated by chromatography on a Sepharose
G-75 column equilibrated in buffer A. The radioactivity of
the excluded tubulin-[3H]GTP was measured after addition
of scintillation liquid.
Results
Several compounds of known structure from marine animals
have been tested as cytotoxic agents on cultured cells. Those
drugs showing a cytotoxic effect (IC5o equal to or lower than
5 juM) on the rat lymphoid cell line (P388) after incubation
for 12 h were selected for further analysis.
Eight compounds were chosen: digonozate triacetate (DT),
bPalau's amine (PA), thiocoraline (T), benzoascididermin (B),
MB-3, mycaperoxide B (MB), ecteinascidin 743 (ET 743) and
isohomohalichondrin B (IHB). Additionally other microtu-
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bule poisons were used as control, including a novel
semisynthetic compound, LL-15. The cytotoxic effects of
the last three compounds (ET 743, IHB and LL-15) were
k
Figure 2 Effect of marine compounds in the cell microtubule network. COS-1 cells were incubated in the absence (a) or the
presence of 3 YM nocodazole (b),51iM LL-15 (c), 1.2 /iM MB (d), 40 nM ET 743 (e), 0.1 pM PA (f), 7pM IHB (g), 0.2 pM DI (h), 0.8
pM T (i), 0.3 pM B (j), 0.1 pM B-3 (k) or 1% DMSO (1). Incubation was carried out for 2h at 37°C and then the cells were fixed and
anti-tubulin antibody was added for immunofluorescence analyses. Scale bar corresponds to 1 gM.Antimitotic products and the microtubule network
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tested by studying the inhibition of COS-l cell growth after
24 h of exposure. IC5os for LL-15 of 0.22+0.02 gM, for ET
743 of 0.11+0.02 gM and for IHB of 1.1+0.2,UM were
obtained. Similar cytotoxic effects to those observed in COS-
1 cells were found on other cells, including HeLa cells from
human origin.
In some cases morphological changes were observed upon
treatment with the last three compounds, therefore they were
tested as possible inhibitors of microtubule assembly. Figure
1 shows that DT, PA, T, B, MB-3 and MB do not change
the microtubule network as determined by immunofluores-
cence analyses. On the other hand, IHB and LL-15 disrupt
the microtubule cytoskeleton, whereas the presence of ET
743, under the described conditions (see legend to Figure 2)
slightly decreases the number of fibres present in the cell
microtubule network. As a positive control, the effect of a
known microtubule inhibitor, nocodazole (Hoeberek et al.,
1976), on the microtubule network is also indicated (Figure
2).
The effect of IHB on cell microtubule assembly is not
surprising as it has been reported that an isomer of that
compound, homohalichondrin B, inhibits microtubule assem-
bly in vitro (Bai et al., 1991). When a similar in vitro analysis
was done using IHB it was observed that it also inhibits in
vitro microtubule assmebly. Tubulin polyermerisation was
inhibited by 50% by the addition of 3 gUM nocodazole, or by
2tM IHB by using the DMSO-induced assembly procedure
described in Materials and methods. An example of this
analysis is given in Figure 3, in which the proportion of
assembled tubulin in the absence (control) or presence of
nocodazole (used as positive control of assembly inhibition)
or IHB is shown. A difference between the drugs is the time
for the reversion of the poison effect, which takes longer for
IHB than for nocodazole (Figure 4). Another difference was
the IHB inhibition of in vitro microtubule assembly was not
prevented by the presence of microtubule-associated proteins
(data not shown). This has also been reported for
homohalichondrin B (Bai et al., 1991). Also, addition of
IHB does not interfere with colchicine binding to tubulin at a
s ....e.'....:....,."''......,'.'',.:.....:.:f'S".,.,.,St..:.
concentration of 20 ,uM. On the other hand, and by analogy
with homohalichondrin B, IHB interferes with GTP binding
to tubulin (Figure 5) and this interference could be the basis
of the inhibitory mechanism of IHB on tubulin assembly.
A different mechanism could be proposed for the action of
LL-15. It disrupts the microtubule network and competes
with colchicine binding to tubulin (4 guM LL-15 inhibits
colchicine binding up to 41%) (see Table I). However, it has
little effect on GTP binding to tubulin (Figure 5). This result
may be explained by the LL-15 structural homology with
podophyllotoxin, a compound that has the above character-
istics with respect to interference with colchicine binding to
tubulin.
Less clear is the effect of ecteinascidin 743 on the
microtubule network. Immunofluorescence analysis (Figure
6) indicates a dramatic rearrangement of the microtubule
network on cultured COS-1 cells when a long incubation
with ET 743 was performed (compare Figures 2 and 6).
Different effects could be observed on microtubule organisa-
tion, with increasing drug treatment time or drug
concentration. First, there was a decrease in the proportion
of assembled microtubules at the cell cytoplasm (Figure 2e),
followed by the appearance of microtubule bundles around
the nuclear membrane (Figure 6). Subsequently, the
appearance of microtubule bundles in other cell localisa-
tions were observed (Figure 6). Those cells treated under the
conditions in which microtubule bundles around the nuclear
membrane were observed were unable to recover when the
drug was washed out. A similar but less pronounced effect
was found when two isomers of ET 743, ecteinascidin 736
(ET 736) and ecteinascidin 735 (ET 735), were tested. In this
way microtubule rearrangements similar to that of ET 743
were observed, (including microtubule bundle formation) for
ET 735 and ET 736 (Figure 7). When HeLa cells were tested
with ET 743 the same effects were observed as for COS-l
cells.
The effect of ET 743 on in vitro microtubule assembly was
tested as described above for IHB. In this case at
concentrations of 1 /uM, 3 1UM and 7 ,UM, assembly was
b
0
e X
0
Figure 3 Characterisation of tubulin present in polymerised form upon incubation with different compounds. Equal amounts of
tubulin (2 mg ml-1) were assembled in the presence of DMSO (see Materials and methods) in the absence (c) or in the presence of2
jM IHB (i) or 2 jIM nocodazole (n). (a) The polymerised protein, in each condition, was pelleted and characterised by gel
electrophoresis. (b) The amount of stained protein was measured, in each case, by densitometry and the patterns obtained in the
absence (-) or presence of IHB (--- -) or nocodazole ( ) are shown and they were taken into account to measure the amount
of polymerised protein.
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Figure 4 Recovery of cells treated with IHB. COS-1 cells were incubated, as indicated in Figure 2, in the presence of 3 gM
nocodazole (a, a') or 7 gM IHB (b, b'). After treatment (2h at 37'C), the cells were either fixed and subjected to immunofluoresence
analyses as indicated above (a, b) or the drugs were washed out and a further incubation of 1 h at 37°C was performed in the
absence of the drugs. After that time the cells were fixed and incubated with anti-tubulin for immunofluorescence analyses (a', b').
Scale bar corresponds to 1 MM.
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Figure 5 Binding of GTP to tubulin in the presence of different
marine compounds. An aliquot of 50 Mg of rat brain tubulin was
incubated with [3H]GTP in the presence of increasing concentra-
tion of ET 743 (A), LL-15 (Cl) or IHB (0). After incubation,
[3H]GTP bound to the protein was measured in each case and the
result is plotted in the figure.
carried out at 90%, 75% and 80% respectively, relative to a
control incubation, in which microtubule assembly was
performed in the absence of the drug. This result indicates
that ET 743 probably does not act directly on tubulin. Also
no interference with colchicine binding to tubulin was
observed at a concentration of 15 jgM ET 743.
Possible interference of ET 743 with GTP binding to
tubulin was analysed. Figure 5 indicates that ET 734 did not
decrease the GTP binding to tubulin.
Table I Colchicine binding to tubulin in the presence of different
compounds
Compound %
None 100
Colcemid 21±5
LL-15 59+ 17
IHB 102+2
ET 743 92+ 12
The colchicine binding to tubulin was assayed as indicated in
Materials and methods, mixing 5 ,UM tubulin with 1 MM [3H]colchicine
in the absence or presence of 10 gM colcemid, 4 gM LL-15, 10 gM IHB
or 1OMm ET 743. The 3H c.p.m. associated to tubulin in the absence of
any added compound (23 500 c.p.m.) was taken as 100%. In the table
isindicated the percentage ofthose counts bound in thepresence ofthe
different compounds tested. The average of three experiments is
indicated.Antimitotic products andthe microtubule network
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Figure 6 Effect of ET 743 on HeLa cell microtubule network. HeLa cells were incubated in the absence (a) or the presence of40 nM (1.5 h)
(b), 400 nM (1.5 h) (c), 4gLM (1.5 h) (d) or 4gM (8 h) (e, e') ET 743. After treatment the cells were subjected to immunofluorescence analyses.
Scale bars correspond to 1 Him (b) and 2 im (d and e).
No effect on the microfilament network was observed when
the cells were treated with IHB or the ecteinascidin isomers.
Also, no significant differences were found in the intermediate
filament network, although filaments are predominantly
located around the cell nucleus (Figures 8 and 9). Figure 8
shows that in the presence of IHB the major cytoskeletal
differences were observed for the microtubule network but not
for the microfilament, or intermediate filament organisation,
despite the localisation of intermediate filaments being mainly
around the cell nucleus. Figure 9 indicates that cell treatment
for ET 743 or its isomers does not affect the intermediate
filaments or microfilament network.
Discussion
Microtubule poisons have been used as anti-tumoral drugs
owing to their effect on cell proliferation. However, it has
been reported that tumour cells, such as some ovarian and
breast carcinoma cells are resistant to some of those drugs
(Beck, 1987; Moscow and Cowan, 1988) and, therefore, new
compounds that prevent cellular proliferation in those or
other cells are under study, and their mechanisms of action
are being analysed.
Several sources have been used for identifying new
microtubule inhibitors such as fungi, plants or chemical
synthesis, and more recently marine animals (Flam, 1994).
These compounds prevent microtubule assembly by different
mechanisms. Some of them, such as nocodazole, have an
effect similar to that of colchicine and may compete with this
drug for its binding to tubulin (Hamel, 1990). Other
compounds may interfere with GTP binding to tubulin and
inhibit the binding of other microtubule poisons, such as
vinca alkaloids to tubulin (Hamel, 1990; Bai et al., 1991).
In the present work three new marine compounds have
been described that interfere with the microtubule network in
cultured cells. These compounds are IBH, ET 743 and LL-15.
The first two compounds are particularly active against lung
cancer, melanoma and breast cancer cell lines (JL Fern'andez-
Puentes, personal communications; Hirata and Uemura,
1986). Two of the compounds (IBH, an isomer of
halichondrin B, and LL-15) break up the microtubuleAntimitotic products and the microtubule network
M Garcia-Rocha et al
Figure 7 Effect ofecteinascidin isomers on HeLa cell microtubule network. HeLa cells were incubated (8h) in the presence of 4 jPM
ET 743 (a, a'); ET 735 (b) and ET 736 (c) and subjected to immunofluorescence analyses using an anti-tubulin antibody. Scale bars
correspond to 2 ,um (a', b) and 1 jym (c).
1 2 3
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b
Figure 8 Effect of IBH on HeLa cytoskeletal components. HeLa cells were incubated for 8h at 37°C in the absence (a) or the
presence of 7 qM IHB (b) and the immunofluorescence analyses using anti-tubulin (1), anti-vimentin (2), anti-actin (3) and
antibodies are indicated.Antimitotic products and the microtubule network
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Figure 9 Effect of ET isomers on HeLa cytoskeletal components. HeLa cells were incubated for 12h at 37°C, in the presence of
4yM ET 735 (a), 4 MM ET 743 (b) and 4yiM ET 736 (c). The reactions with anti-tubulin (1), anti-vimentin (2) and anti-actin (3) are
indicated. Scale bars correspond to 10 gm.
network by direct interaction with tubulin, resulting in the
decreased binding of GTP to the protein, essential for tubulin
polymerisation. This result, indicating the mechanism of
action of IHB on microtubule protein, is consistent with
results of other isomers of this drug and related drugs (Bai et
al., 1991; 1990). Also, LL-15 behaves like its structural
homologue podophyllotoxin with respect to its interference
with colchicine binding (Wilson, 1970; Hamel, 1990).
However, preliminary results (M Garcia-Rocha, unpub-
lished) indicate that LL-15 is less active than podophyllotox-
in as a microtubule poison. This may be due to the alteration
of the lactose D ring (Hamel, 1990) in LL-15. Indeed, a
related compound, LL-16 (Figure 1) in which that ring
is missing, shows no activity on microtubule protein
(M Garcia-Rocha, unpublished).
The effect of compound ET 743 on cultured cells is
surprising as it promotes as a first step a decrease in the
proportion of microtubules located close to the cell
membrane and afterwards it results in the appearance of
collapsed microtubules surrounding the cell nucleus. It thus
appears to change the microtubule distribution to that of
curved microtubules forming a circle around the cell nucleus,
whereas in control cells microtubules are arranged in a line
from the centrosome to the cell membrane. It seems that,
with ET 743, microtubules are not anchored at the
centrosome, a feature observed upon taxol addition
(another microtubule drug) (Schiff et al., 1979). However,
in the presence of taxol microtubule polymers are mainly
located around the cell membrane. Nevertheless, the
appearance of some microtubule bundles in the presence of
ET 743 may resemble the action of taxol. However, taxol
facilitates microtubule assembly (Schiff et al., 1979) and it has
been found that at concentrations of up to 4 gM, ET 743
does not increase in vitro microtubule polymerisation.
Several analyses have been done to test the possible
mechanisms of ET 743 on microtubule protein and the results
have indicated that it does not interfere with colchicine or
GTP binding to tubulin. Also, as indicated above, it appears
that it does not produce a decrease in the in vitro
polymerisation of tubulin. Thus, molecules other than
tubulin could be the target for ET 743. Those molecules
may indirectly affect microtubule stability or produce the
perinuclear arrangement of curved microtubules described
above.
Nevertheless, an important feature observed in the
presence of ET 743 is the microtubule curvature and the
fact that microtubules collapse around the nucleus. This
appearance may suggest the absence of any guidance element
that prevents the elongation of centrosomal microtubules to
the cell periphery. However, there is no known protein with
that characteristic inside a cell, as intermediate filaments that
co-localise with microtubules could not be involved as it has
been reported that in the absence of an intermediate filament
network, no changes in the microtubule network were
observed (Klymkowsky, 1981).
In summary, three different compounds, from marine
organisms, show different effects on microtubule organisa-
tion. IHB interferes with GTP binding to tubulin, LL-15
probably acts on tubulin in the same way as podophyllotoxin
(see Hamel, 1990) and ET 743 has a novel effect on
microtubule distribution in cultured cells. The mechanism
of action of ET 743 appears different to those previously
described for microtubule inhibitors.
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